Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) completed enrollment with 166 participants randomized; topline results expected mid 2027 Randomized the first participant in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in individuals with T1D who use hybrid closed-loop (HCL) insulin delivery systems Company hosted a Key Opinion Leader (KOL) event in October, highlighting cadisegliatin and its potential to address hypoglycemia in people wit
I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be vTv Therapeutics (VTVT).
HIGH POINT, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 20, 2026, at 2:30 PM ET. To register, click here. The event will feature leading T1D experts Schafer Boeder, MD (Paradigm Clinical Research, University of California San Diego), Klara Kle
Detailed price information for Vtv Theraptcs Cl A (VTVT-Q) from The Globe and Mail including charting and trades.
HIGH POINT, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule
Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.
HIGH POINT, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in September: H.C. Wainwright 28th Annual Global Investment ConferenceFormat: Fireside Chat and one-on-one investor meetingsDate: Wednesday, September 16, 2026Time: 10:00-10:30 AM ETLocation: Ne
This is the newest page. Registered accounts read further back.